Combined radiofrequency ablation and adjuvant liposomal chemotherapy: Effect of chemotherapeutic agent, nanoparticle size, and circulation time

Journal of Vascular and Interventional Radiology

Volumn 16, Issue 10, 2005, Pages 1365-1371

  Ahmed, Muneeb ^a   Lukyanov, Anatoly N ^b   Torchilin, Vladimir ^b   Tournier, Herve ^c   Schneider, Anatoly N ^c   Goldberg, S Nahum ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c Bracco Suisse SA   (Switzerland)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIPALMITOYL SN GLYCERO 3 PHOSPHATIDIC ACID; ANTINEOPLASTIC AGENT; CISPLATIN; DIPALMITOYLPHOSPHATIDYLGLYCEROL; DOXORUBICIN; FLUOROURACIL; LIPOSOME; MACROGOL 2000; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CATHETER ABLATION; CELL STRAIN R3230; CIRCULATION TIME; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; DRUG INTERSTITIUM LEVEL; DRUG TISSUE LEVEL; DRUG UPTAKE; EXPERIMENTAL NEOPLASM; INTERSTITIUM; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN DENATURATION; RAT; TISSUE COAGULATION; TUMOR NECROSIS;

EID: 26844498590     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000175324.63304.25     Document Type: Article

References (40)

1. Posteraro AF, Dupuy DE, Mayo-Smith WW. Radiofrequency ablation of bony metastatic disease. Clin Radiol 2004; 59:803-811.
2. Hines-Peralta A, Goldberg SN. Review of radiofrequency ablation for renal cell carcinoma Clin Cancer Res 2004; 10(suppl):6328S-6334S.
3. Decadt B, Siriwardena AK. Radiofrequency ablation of liver tumours: systematic review. Lancet Oncol 2004; 5:550-560.
4. Goldberg SN, Ahmed M. Minimally invasive image-guided therapies for hepatocellular carcinoma. J Clin Gastroenterol 2002; 35(suppl):S115-S129.
5. Wood BJ, Bates S. Radiofrequency thermal ablation of a splenic metastasis. J Vasc Interv Radiol 2001; 12:261-263.
6. Gervais DA, Arellano RS, Mueller PR. Percutaneous radiofrequency ablation of nodal metastases. Cardiovasc Intervent Radiol 2002; 25:547-549.
7. Dupuy DE, Monchik JM, Decrea C, Pisharodi L. Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery 2001; 130:971-977.
8. Dupuy D, Goldberg S. Image-guided radiofrequency tumor ablation: Challenges and opportunities-Part II. J Vasc Interv Radiol 2001; 12:1135-1148.
9. Dodd GD III, Soulen MC, Kane RA, et al. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics 2000; 20:9-27.
10. Rhim H, Dodd GD III. Radiofrequency thermal ablation of liver tumors. J Clin Ultrasound 1999; 27:221-229.
11. Wood TF, Rose DM, Chung M, et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000; 7:593-600.
12. Livraghi T, Meloni F, Goldberg SN, et al. Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions. Radiology 2000; 214:761-768.
13. Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radiofrequency ablation of hepatic metastases from colorectal cancer: long term results in 117 patients. Radiology 2001; 221:159-166.
14. Ahmed M, Goldberg SN. Combination radiofrequency thermal ablation and adjuvant intravenous liposomal doxorubicin increases tissue coagulation and intratumoral doxorubicin. Int J Hypertherm 2004; 20:781-802.
15. Exner AA, Weinberg BD, Stowe NT, et al. Quantitative computed tomography analysis of local chemotherapy in liver tissue after radiofrequency ablation. Acad Radiol 2004; 11:1326-1336.
16. Gaber MH, Wu NZ, Hong K, et al. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 1996; 36:1177-1187.
17. Kong G, Anyarambhatla G, Petros WP, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 2000; 60:6950-6957.
18. Goldberg SN, Girnan GD, Lukyanov AN, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology 2002; 222:797-804.
19. Monsky WL, Kruskal JB, Lukyanov AN, et al. Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model. Radiology 2002; 224:823-829.
20. Goldberg SN, Kamel IR, Kruskal JB, et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. AJR Am J Roentgenol 2002; 179:93-101.
21. Ahmed M, Monsky WE, Girnun GD, et al. Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation. Cancer Res 2003; 63: 6327-6333.
22. Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993; 10:703-708.
23. Goldberg SN, Kruskal JB, Oliver BS, et al. Percutaneous tumor ablation: increased coagulation by combining radiofrequency ablation and ethanol instillation in a rat breast tumor model. Radiology 2000; 217:827-831.
24. Liszczak TM, Hedley-Whyte ET, Adams JF, et al. Limitations of tetrazolium salts in delineating infarcted brain. Acta Neuropathol (Berl) 1984; 65:150-157.
25. Goldberg SN, Saldinger PF, Gazelle GS, et al. Percutaneous tumor ablation: increased coagulation necrosis with combined radiofrequency and percutaneous doxorubicin injection. Radiology 2001; 220:420-427.
26. Gabizon A, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 1989; 81: 1484-1488.
27. Cummings J, McArdle CS. Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug. Br J Cancer 1986; 53:835-838.
28. Ahmed M, Liu Z, Lukyanov AN, et al. Radiofrequency increases intratumoral doxorubicin accumulation and tumor coagulation in multiple tissues and tumor types. Radiology (in press).
29. D'Ippolito G, Ahmed M, Girnan GD, et al. Percutaneous tumor ablation: increased endpoint survival with combined radiofrequency ablation and liposomal doxorubicin in a rat breast tumor model. Radiology 2003; 228:112-118.
30. Gervais DA, McGovern FJ, Arellano RS, et al. Renal cell carcinoma: clinical experience and technical success with radio-frequency ablation of 42 tumors. Radiology 2003; 226:417-424.
31. Fornage BD, Sneige N, Ross MI, et al. Small (< or = 2-cm) breast cancer treated with US-guided radiofrequency ablation: feasibility study. Radiology 2004; 231:215-224.
32. Lencioni R, Crocetti L, Cioni R, et al. Radiofrequency ablation of lung malignancies: where do we stand? Cardiovasc Intervent Radiol 2004; 27:581-590.
33. Mayo-Smith WW, Dupuy DE. Adrenal neoplasms: CT-guided radiofrequency ablation-preliminary results. Radiology 2004; 231:225-230.
34. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001; 61:3027-3032.
35. Kruskal JB, Oliver B, Huertas JC, Goldberg SN. Dynamic intrahepatic flow and cellular alterations during radiofrequency ablation of liver tumors in mice. J Vasc Interv Radiol 2001; 12:1193-1201.
36. Dudar TE, Jain RK. Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res 1984; 44:605-612.
37. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000; 89:1037-1047.
38. Hong RL, Tseng YL. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 2001; 91: 1826-1833.
39. Mayhew EG, Goldrosen MH, Vaage J, Rustum YM. Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38. J Natl Cancer Inst 1987; 78:707-713.
40. Storm G, Roerdink FH, Steerenberg PA, et al. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Cancer Res 1987; 47:3362-3372.